Endothelial dysfunction and/or injury is pivotal to the development of cardiovascular and inflammatory pathology. Endothelial dysfunction and/or injury has been described in Human Immunodeficiency Virus (HIV) infection. Elaboration of circulating markers of endothelial activation, such as soluble adhesion molecules and procoagulant proteins, occurs in HIV infection. Certain endothelial cells, such as those lining liver sinusoids, human umbilical vein endothelial cells, bone marrow stromal endothelial cells or brain microvascular endothelial cells, have been shown to be variably permissive for HIV infection. Entry of virus into endothelial cells may occur via CD4 antigen or galactosyl-ceramide receptors. Other mechanisms of entry including chemokine receptors have been proposed. Nevertheless, endothelial activation may also occur in HIV infection either by cytokines secreted in response to mononuclear or adventitial cell activation by virus or else by the effects of the secreted HIV-associated proteins, gp 120 (envelope glycoprotein) and Tat (transactivator of viral replication) on endothelium. Enhanced adhesiveness of endothelial cells, endothelial cell proliferation and apoptosis as well as activation of cytokine secretion have all been demonstrated. Synergy between select inflammatory cytokines and viral proteins in inducing endothelial injury has been shown. In HIV infection, dysfunctional or injured endothelial cells potentiate tissue injury, inflammation and remodeling, and accelerate the development of cardiovascular disease.

Sepsis, a major clinical problem with high morbidity and mortality, is caused by overwhelming systemic host-inflammatory response. Toll-like receptors (TLRs) play a fundamental role in induction of hyperinflammation and tissue damage in sepsis. In this study, we demonstrate a protective role of TLR9 inhibition against the dysregulated inflammatory response and tissue injury in sepsis. TLR9 deficiency decreased the mortality of mice following cecal ligation and puncture (CLP)-induced sepsis. TLR9 knockout mice showed dampened p38 activation and augmented Akt phosphorylation in the spleen, lung and liver. In addition, TLR9 deficiency decreased the levels of inflammatory cytokines and attenuated splenic apoptosis after CLP. These results indicate that TLR9 inhibition might offer a novel therapeutic strategy for the management of sepsis.

Opioids are powerful pain relievers, but also potent inducers of dependence and tolerance. Chronic morphine administration (via subcutaneous pellet) induces morphine dependence in the nucleus accumbens, an important dependence region in the brain, yet the cellular mechanisms are mostly unknown. Toll-like receptor 2 (TLR2) plays an essential function in controlling innate and inflammatory responses. Using a knockout mouse lacking TLR2, we assessed the contribution of TLR2 to microglia activation and development of morphine dependence. We report here that mice deficient in TLR2 inhibit morphine-induced the levels of microglia activation and proinflammatory cytokines. Moreover, in TLR2 knockout mice the main symptoms of morphine withdrawal were significantly attenuated. Our data reveal that TLR2 plays a critical role in morphine-induced microglia activation and dependence.

These studies evaluated the effects treatment with glucan phosphate, a soluble polysaccharide immunomodulator, on the inflammatory response induced by burn injury and on resistance to Pseudomonas aeruginosa burn wound infection. Mice were exposed to 35% total body surface area burns and were resuscitated with lactated Ringer's (LR) solution alone or LR supplemented with glucan phosphate (40 mg/kg). Glucan phosphate treatment attenuated burn-induced expression of interleukin (IL)-1β, IL-6, and IL-10 mRNAs in spleen, lung, and heart. Plasma concentrations of IL-1β, IL-6, macrophage inflammatory protein (MIP)-2, and IL-10 were also decreased in burned mice treated with glucan phosphate compared with vehicle-treated controls. Early postburn mortality was not significantly different between control (20%) and glucan phosphate-treated (10%) mice, but there was a small improvement in acid-base balance in the glucan phosphate-treated group. Mice received a second injection of glucan phosphate or LR on day 4 postburn and were infected by topical application of P. aeruginosa to the burn wound on day 5. Glucan phosphate treatment significantly improved survival in mice exposed to P. aeruginosa burn wound infection. The improved survival correlated with lower bacterial burden in the burn wound, attenuated production of proinflammatory cytokines, and enhanced production of Th1 cytokines. These studies show that glucan phosphate treatment attenuates burn-induced inflammation and increases resistance to P. aeruginosa burn wound infection in an experimental model of burn injury.

Glucans are fungal cell wall glucose polymers that are released into the blood of infected patients. The role of glucans in infection is unknown. We examined serum glucan and cytokine levels in intensive care unit (ICU) patients with infections. There was an inverse correlation (p<0.001) between serum glucan levels and interleukin (IL)-2), IL-4, tumor necrosis factorα (TNFα) and granulocyte macrophage-colony stimulating factor (GM-CSF) levels in infected ICU patients. The correlation between serum cytokines and serum glucan was only observed at glucan concentrations <40 pg/ml. No change was observed at serum glucan levels of >40 pg/ml. There was no correlation between serum glucan levels and systemic levels of IL-1β, IL-5, IL-6, IL-8, IL-10 or IFNγ. Interestingly, blood borne glucans did not suppress systemic cytokine levels in infected ICU patients, instead they were maintained at control levels. We conclude that circulating glucans may prevent cytokine upregulation in response to infection. This may represent an adaptive response to septic injury.

No description available.

Human endothelium is capable of expressing a variety of molecules, including cytokines and growth factors, critical to inflammation. This aspect of coronary endothelium has not been studied in detail. In this study, we report, for the first time, expression of multifunctional cytokines by human coronary artery endothelial cells (HCAEC) and their regulation by inflammatory cytokines and glucocorticoids. We also compared expression of cytokine transcripts in two additional cell lines derived from pulmonary artery (HPAEC) and umbilical vein (HUVEC) endothelium. HCAEC expressed transcripts for interleukin 5 (IL-5), IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) constitutively. Induction of IL-1α, IL-6, granulocyte- macrophage colony-stimulating factor (GM-CSF), and MCP-1 was seen following treatment with TNFα. We found no expression of IL-1RA, IL-2, IL-4, IL-13, TNF-α, or IFN-γ in HCAEC. IL-1β and TNF-α synergistically induced IL-6 and GM-CSF and additively induced IL-8 and MCP-1 production, while IL-2, IL- 10, IFN-α, and IFN-γ had little or no additional effects. Interestingly, no IL-1α or IL-5 protein product was found even after maximal stimulation of HCAEC. No significant differences were seen in the profile of cytokine genes expressed by HCAEC, HPAEC, or HUVEC. Glucocorticoids inhibited IL-8 production from all three cell lines. This study demonstrates that human coronary endothelial cells are capable of expressing a wide variety of multifunctional cytokines which may be of relevance to vascular inflammation.

Over 270 million people play soccer worldwide, and its popularity grows every day. In team sport exercise, fatigue may result from numerous factors including limited fuel, depleted energy stores and production of compounds that promote an inflammatory response. While inflammation is an essential mechanism for repairing damaged muscle tissue with exercise, prolonged inflammation leads to increased production of reactive oxygen species that can damage cell membranes, muscle, and signaling proteins. To prevent this response and improve performance, athletes are increasingly looking to nutritional interventions. Carbohydrate and antioxidant supplementation have both shown evidence of producing an ergogenic effect and attenuating inflammation and oxidative stress with prolonged endurance exercise. Less is known about how these interventions may influence intermittent, high-intensity exercise characteristic of soccer. In particular, this exercise presents a unique challenge in that opportunities for nutrient intake are limited to pre-game and half-time. In our first study, we had 10 male collegiate soccer players perform a 90-min. soccer-simulation test, that we developed, which was followed by a progressive shuttle run (PSR) test to exhaustion. They consumed a honey-sweetened beverage (H), a sports drink (S), or a placebo (P) before and half-way through the protocol. Both H and S provided 1.0 g·kg⁻¹ carbohydrate and ~17.6 mL·kg⁻¹ total volume for each trial. Overall, the test resulted in increased fatigue and production of inflammatory markers and antioxidant capacity. There was no significant difference between treatments for any performance measure. Mean times for a high intensity run and rating of perceived exertion increased with time, and there was an overall decrease in PSR time compared to baseline (-22.9%). There was a rise in glucose (15.6%), IL-6 (548%), IL-1ra, IL-10 (514%) and ORAC (15%) post-test but no change in cortisol. Insulin was significantly lower by 1 h-post. IL-1ra levels increased post-test for H (25.8%), S (65.5%), and P (63.9%), but the change for H was less than the other treatments. No treatment effects for the other blood measures were observed. The lack of an ergogenic effect of carbohydrate on soccer performance calls into question the benefit of supplementation at a frequency typical of a regulation soccer match in highly trained athletes with adequate energy stores. Since acute carbohydrate ingestion in the first study did not attenuate some markers of inflammation (e.g. IL-6), we chose to focus on an alternative theory for the rise in inflammatory markers with strenuous exercise in our second study. One aspect of soccer, repeated sprinting, results in increased ROS production partially through the activation of the enzyme xanthine oxidase (XO). Quercetin, a flavonol in plants that has shown some ergogenic effects with endurance exercise, inhibits XO in vitro. The effect of quercetin on team sport exercise had not been studied. We gave recreationally active males a commercial sports drink (S) or S + 500 mg of quercetin (Q) 2x/d for 1 wk prior to a repeated sprint test (RST). Sprint times increased (5.9%) for both treatments as did plasma XO activity (47%), IL-6 (77%), and uric acid (25%) from pre-test to post-test. Q supplementation did not attenuate plasma XO activity or IL-6 and actually increased one calculated index of fatigue, percent fatigue decrement (5.1%- Q and 3.8%- P). These findings add to the growing body of literature that quercetin supplementation does not attenuate exercise-induced inflammation and oxidative stress in vivo. Collectively, this research has practical implications for sports drink companies who are exploring the use of flavonoid compounds in product formulation. Specifically, they should reconsider adding quercetin to their beverages if they are marketing to team sport athletes. Also, soccer players should be made aware that, at ingestion frequencies typical of a soccer match, they may not expect a significant performance benefit from acute carbohydrate supplementation. / Ph. D.

The therapy suppressive tumour microenvironment (TME) continues to hinder anti-cancer therapies. Local delivery of therapeutic proteins, including potentially toxic factors, is increasingly needed to enhance immunotherapeutic bioactivities and minimize systemic toxicity. To this end, we are developing vehicles that immobilize to extracellular matrix (ECM) components upregulated in TME for localization of polymer-grafted bioactive cytokines with tunable degradation rates to control cytokine clearance. The grafted cytokine would be bioactive, and the length of the therapy would be governed by the degradation kinetics of the hydrolytic linker between the cytokine and polymer. The cytokines were expressed and purified, and their biological activity was confirmed. Click chemistry was used to graft the therapeutic proteins and collagen-binding peptides to the copolymer. Production of the therapeutic carriers was confirmed by SEC and fluorescent measurements. Biolayer interferometry and tracking immobilization inside collagen gel confirmed the binding affinity between carriers and collagen type 1. In vitro studies confirmed the bioactivity of the carriers in the presence of T-cells and macrophages. In summary, ECM binding vehicles for local sustained protein release will aid in the local delivery of therapeutic proteins to alter TME and promote immunotherapies. Screens will be conducted in multicellular spheroid models to identify bioactive formulations. / Thesis / Master of Science (MSc)

No description available.